Advertisement

Lung Cancer

  • Jigar Shah
  • Tarek Mekhail
Part of the Current Clinical Oncology book series (CCO)

Abstract

In the United States, 172,570 new cases of lung cancer will be diagnosed in the year 2005 and 163,510 of these patients will die of the disease (1). Lung cancer is currently the leading cause of cancer death in men and has now surpassed breast cancer in women (2, 3, 4, 5, 6, 7). The median age at diagnosis is approx 60 yr. The highest incidence of lung cancer is noticed among Hawaiians and African-Americans in United States, and in Scotland and Wales, worldwide (8).

Keywords

Lung Cancer Bone Metastasis Clin Oncol Zoledronic Acid Natl Cancer Inst 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jemal A, Murray T, Ward E, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005; 55:10–30.PubMedGoogle Scholar
  2. 2.
    Travis WD, Lubin J, Ries L, Devesa S. United States lung cancer incidence trends. Cancer 1996; 77:2464–2470.PubMedCrossRefGoogle Scholar
  3. 3.
    Parkin DM, Pisani P, Perlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54:594–606.PubMedCrossRefGoogle Scholar
  4. 4.
    Parkin DM, Pisani P, Perlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 1993; 55:891–903.PubMedCrossRefGoogle Scholar
  5. 5.
    Cersosimo RJ. Lung cancer: a review. Am J Health Syst Pharm 2002; 59:611–642.PubMedGoogle Scholar
  6. 6.
    Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics, 2002. CA Cancer J Clin 2002; 52:23–47.PubMedGoogle Scholar
  7. 7.
    Schottenfeld D. Etiology and epidemiology of lung cancer. In: Pass HI, Mitchell JB, Johnson DH, et al,. eds. Lung Cancer: Principles and Practice. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins 2000:367–388.Google Scholar
  8. 8.
    Glisson BS, McKenna RJ, Movsas B. Small-cell lung cancer. In: Pazdur R, Coia LR, Hoskins WJ, et al. eds. Cancer Management: A Multidisciplinary Approach, 7th ed. New York, NY: The Oncology Group; 2003;107.Google Scholar
  9. 9.
    Cole P, Rodu B. Declining cancer mortality in the United States. Cancer 1996; 78:2045–2048.PubMedCrossRefGoogle Scholar
  10. 10.
    Vaporciyan AA, Kies MS, Stevens CW, et al. Cancer of the lung. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., eds. Cancer Medicine, 6th ed. Spain, BC Decker Inc 2003; 1385.Google Scholar
  11. 11.
    Stellman SD, Garfinkel L. Smoking habits and tar levels in a new American Cancer Society prospective study of 1.2 million men and women. J Natl Cancer Inst 1986; 76:1057–1063.PubMedGoogle Scholar
  12. 12.
    Lubin JH, Blot WJ, Berrino F, et al. Patterns of lung cancer risk according to type of cigarette smoked. Int J Cancer 1984; 33:569–576.PubMedCrossRefGoogle Scholar
  13. 13.
    Wilcox H, Schoenberg J, Mason T, Bill JS, Stemhagen A. Smoking and lung cancer: risk as a function of cigarette tar content. Prev Med 1988; 17:263–272.PubMedCrossRefGoogle Scholar
  14. 14.
    US Environmental Protection Agency. Respiratory health effects of passive smoking: Lung Cancer and other disorders. 1992.Google Scholar
  15. 15.
    Coultas DB, Samet JM. Occupational lung cancer. Clin Chest Med 1992; 13:341–354.PubMedGoogle Scholar
  16. 16.
    Omenn GS, Merchant J, Boatmann E, et al. Contribution of environmental fibers to respiratory cancer. Environ Health Prespect 1986; 70:51–56.CrossRefGoogle Scholar
  17. 17.
    Doll R. Mortality from lung cancer in asbestos workers. Bri J Intern Med 1955; 12:81–86.Google Scholar
  18. 18.
    Kjuus H, Skjaerven R, Langard S. A case-referent study of lung cancer, occupational exposure, and smoking II: role of asbestos exposure. Scand J Work Environ Health 1986; 12:203–209.PubMedGoogle Scholar
  19. 19.
    Saccomanno G, Archer VE, Saunders RP, Auerbach O, Klein MG. Early indices of cancer risk among uranium miners with reference to modifying factors. Ann NY Acad Sci 1976; 271:377–383.PubMedCrossRefGoogle Scholar
  20. 20.
    Gilliland FD, Hunt WC, Pardilla M, Key CR. Uranium mining and lung cancer among Navajo men in New Mexico and Arizona: 1969–1993. J Occup Environ Med 2000; 42:278–283.PubMedCrossRefGoogle Scholar
  21. 21.
    Lubin JH, Boice JD, Edling C, et al. Lung cancer in radon-exposed miners and estimation of risk from indoor exposure. J Natl Cancer Inst 1995; 87:817–827.PubMedCrossRefGoogle Scholar
  22. 22.
    Schottenfeld D. Epidemiology of lung cancer. In: Pass HI, Mitchell HB, Johnson DH, et al., eds. Lung Cancer: Principles and Practice, Philadelphia, PA: Lippincott-Raven; 1996:305–321.Google Scholar
  23. 23.
    Goodman GE. Prevention of lung cancer. Crit Rev Oncol Hematol 2000; 33:187–197.PubMedCrossRefGoogle Scholar
  24. 24.
    Yang P, Wentzlaff KA, Katzmann JA, et al. Alpha1 antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol Biomarkers Prev 1998; 8:461–465.Google Scholar
  25. 25.
    Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64:235–248.PubMedCrossRefGoogle Scholar
  26. 26.
    Weinberg RA. Tumor suppressor genes. Science 1991; 254:1138–1146.PubMedCrossRefGoogle Scholar
  27. 27.
    Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 1983; 306:194–196.PubMedCrossRefGoogle Scholar
  28. 28.
    Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91:1194–1210.PubMedCrossRefGoogle Scholar
  29. 29.
    Schneider PM, Hung MC, Chiocca SM, et al. Differential expression of the c-erbB-2 gene in human small cell and non-small-cell lung cancer. Cancer Res 1989; 49:4968–4971.PubMedGoogle Scholar
  30. 30.
    Weiner DB, Nordberg J, Robinson R, et al. Expression of the neu gene-encoded protein (P185neu) in human non-small-cell carcinomas of the lung. Cancer Res 1990; 50:421–425.PubMedGoogle Scholar
  31. 31.
    Suzuki H, Takahashi T, Kuroishi T, et al. p53 mutations of nonsmall-cell lung cancer in Japan: association between mutations and smoking. Cancer Res 1992; 52:734–736.PubMedGoogle Scholar
  32. 32.
    Vahakangas KH, Samet JM, Metcalf RA, et al. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 1992; 339:576–580.PubMedCrossRefGoogle Scholar
  33. 33.
    The World Health Organization histological typing of lung tumors. Second edition. Am J Clin Pathol 1982; 77:123–136.Google Scholar
  34. 34.
    Travis WD. Pathology of lung cancer. Clin Chest Med 2002; 23:65–81.PubMedCrossRefGoogle Scholar
  35. 35.
    Geddes DM. The natural history of lung cancer: a review based on rates of tumor growth. Br J Dis Chest 1979; 73:1–17.PubMedCrossRefGoogle Scholar
  36. 36.
    Hammar SP, Bolan JW, Bockus D, Remington F, Friedman S. Ultrastructural and immunohistochemical features of common lung tumors: an overview. Ultrastruct Pathol 1985; 9:283–318.PubMedCrossRefGoogle Scholar
  37. 37.
    Travis WD, Travis LB, Devesa SS. Lung cancer. [Published erratum appears in Cancer 1995; 75:2979]. Cancer 1995; 75:191–202.PubMedCrossRefGoogle Scholar
  38. 38.
    Ginsberg RJ, Vokes EE, Rosenzweig K. Non-small cell lung cancer. In DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia, PA: Lippincott Williams and Williams; 2001:925–983.Google Scholar
  39. 39.
    Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung: histologic characteristics and prognosis. Cancer 1995; 75:2844–2852.PubMedCrossRefGoogle Scholar
  40. 40.
    Hasleton PS, Gomm S, Blair V, Thatcher N. Pulmonary carcinoid tumours: a clinicopathological study of 35 cases. Br J Cancer 1986; 54:963–967.PubMedGoogle Scholar
  41. 41.
    Jensen RT, Norton JA. Carcinoid tumours and the carcinoid syndrome. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th ed. Philadelphia, PA: Lippincott-Raven; 1997:1704–1723.Google Scholar
  42. 42.
    Greenberg RS, Baumgarten DA, Clark WS, Isacson P, McKeen K. Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors. Cancer 1987; 60:2476–2483.PubMedCrossRefGoogle Scholar
  43. 43.
    Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a statistical evaluation of 748 reported cases. J Exp Clin Cancer Res 1999; 18:133–141.PubMedGoogle Scholar
  44. 44.
    Ricci C, Patrassi N, Massa R, Mineo C, Benedetti-Valentini FJ. Carcinoid syndrome in bronchial adenoma. Am J Surg 1973; 126:671–677.PubMedCrossRefGoogle Scholar
  45. 45.
    Feldman JM. Carcinoid tumors and the carcinoid syndrome. Curr Probl Surg 1989; 26:835–885.PubMedCrossRefGoogle Scholar
  46. 46.
    Grahame-Smith DG. The carcinoid syndrome. Am J Cardiol 1968; 21:376–387.PubMedCrossRefGoogle Scholar
  47. 47.
    Johnson BE. Management of small cell lung cancer. Clin Chest Med 2002; 23:225–239.PubMedCrossRefGoogle Scholar
  48. 48.
    Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics: 2001. CA Cancer J Clin 2001; 51:15–36.PubMedGoogle Scholar
  49. 49.
    Guinee DG Jr, Fishback NF, Koss MN, Abbondanzo SL, Travis WD. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol 1994; 102:406–414PubMedGoogle Scholar
  50. 50.
    Murren J, Glatstein E, Pass HI. Small cell lung cancer. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Prac tice of Oncology, 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:983–1018.Google Scholar
  51. 51.
    Kraut M, Wozniak A. Clinical presentation. In: Pass HI, Mitchell JB, Johnson DH, et al. eds. Lung Cancer: Principles and Practice, 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2000:521–534.Google Scholar
  52. 52.
    Pancoast HK. Importance of careful roentgen-ray investigations of apical chest tumors. JAMA 1924; 83:1407–1411.Google Scholar
  53. 53.
    Pancoast HK. Superior sulcus pulmonary tumor: Tumor characterized by pain, Honrner’s syndrome, destruction of bone, and atrophy of hand muscles. JAMA 1932; 99:1391–1396.Google Scholar
  54. 54.
    Arcasoy SM, Jett RJ. Superior pulmonary sulcus tumors and Pancoast’s syndrome. N Engl J Med 1997; 337:1370–1376.PubMedCrossRefGoogle Scholar
  55. 55.
    Komaki R. Preoperative radiation therapy for superior sulcus lesions. Chest Surg Clin North Am 1991; 1:13–35.Google Scholar
  56. 56.
    MacDonald RA, Robbins SL. The significance of nonbacterial thrombotic endocarditis: an autopsy and clinical study of 78 cases. Ann Intern Med 1957; 46:255–273.PubMedGoogle Scholar
  57. 57.
    Anderson HA, Prakash UBS. Diagnosis of symptomatic lung cancer. Semin Respir Med 1982; 3:165–169.CrossRefGoogle Scholar
  58. 58.
    Graus F, Elkon KB, Cordon-Cardo C, et al. Sensory neuropathy and small cell lung cancer. Am J Med 1986; 80:45–52.PubMedCrossRefGoogle Scholar
  59. 59.
    Brennan LV, Craddock PR. Limbic encephalopathy as a nonmetastatic complication of oat cell lung cancer: its reversal after treatment of the primary lung lesion. Am J Med 1983; 75:518–520.PubMedCrossRefGoogle Scholar
  60. 60.
    Ojeda VJ. Necrotizing myelopathy associated with malignancy: a clinicopathologic study of two cases and literature review. Cancer 1984; 53:1115–1123.PubMedCrossRefGoogle Scholar
  61. 61.
    Schuffler MD, Baird HW, Fleming CR, et al. Intestinal pseudoobstruction as the presenting manifestation of small-cell carcinoma of the lung: a Paraneoplastic neuropathy of the gastrointestinal tract. Ann Intern Med 1983; 98:129–134.PubMedGoogle Scholar
  62. 62.
    Kimmel DW, O’Neil BP, Lennon VA. Subacute sensory neuropathy associated with small cell lung carcinoma: diagnosis aided by authimmune serology. Mayo Clin Proc 1988; 63:29-PubMedGoogle Scholar
  63. 63.
    Sodhi N, Camilleri M, Camoriano JK, Low PA, Fealey RD, Perry MC. Autonomic function and motility in intestinal pseudo obstruction caused by paraneoplastic syndrome. Dig Dis Sci 1989; 34:1937–1942.PubMedCrossRefGoogle Scholar
  64. 64.
    Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111:1710–1717.PubMedCrossRefGoogle Scholar
  65. 65.
    American Joint Committee on Cancer (AJCC): Lung. In: Fleming ID, Cooper JS, Hensen DE, et al. eds. Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott-Raven; 1997:127.Google Scholar
  66. 66.
    International Union Against Cancer (UICC): Lung and Pleural Tumors. In: Hermanek P, Hutter RVP, Sobin L, eds. TNM Atlas. 4th ed. New York, NY: Wiley-Liss; 1997.Google Scholar
  67. 67.
    Mountain CF. Staging classification of lung cancer: a critical evaluation. Clin Chest Med 2002; 23:103–121.PubMedCrossRefGoogle Scholar
  68. 68.
    Fischer BMB, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2001; 2:659–666.PubMedCrossRefGoogle Scholar
  69. 69.
    Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable nonsmall cell lung cancer. J Thorac Cardiovasc Surg 2003; 126:1943–1951.PubMedCrossRefGoogle Scholar
  70. 70.
    Wingo PA, Tong T, Bolden S. Cancer statistics. Cancer J Clin 1995; 45:8–30.CrossRefGoogle Scholar
  71. 71.
    Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP. Molecular mechanisms of cancer pain. Nat Rev Cancer 2000; 2:201–209.CrossRefGoogle Scholar
  72. 72.
    Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain, and painrelated neurochemical reorganization of the spinal cord. Nat Med 2000; 6:521–528.PubMedCrossRefGoogle Scholar
  73. 73.
    Mundy GR. Metastasis to bone: causes, consequences, and theraputic opportunities. Nat Rev Cancer 2002; 2:584–593.PubMedCrossRefGoogle Scholar
  74. 74.
    Boyde A, Maconnachie E, Reid SA, Delling G, Mundy GR. Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Electron Microsc 1986; 4:1537–1554.Google Scholar
  75. 75.
    Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid homrone related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991; 51:3059–3061.PubMedGoogle Scholar
  76. 76.
    Bryden AA, Hoyland JA, Freemont AJ, et al. Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases. Br J Cancer 2002; 86:322–403.PubMedCrossRefGoogle Scholar
  77. 77.
    Miki T, Yano S, Hanibuchi M, Sone S. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol Res 2001; 12:209–217.Google Scholar
  78. 78.
    Henderson M, Danks J, Moseley J, et al. Parathyroid hormonerelated protein production by breast cancers, improved survival, and reduced bone metastases. J Natl Cancer Inst 2001; 93:234–237.PubMedCrossRefGoogle Scholar
  79. 79.
    Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast-cancer-mediated osteolysis. J Clin Invest 1996; 98:1544–1549.PubMedCrossRefGoogle Scholar
  80. 80.
    Moseley JM, Kubota M, Diefenbach-Jagger H, et al. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA 1987; 84:5048–5052.PubMedCrossRefGoogle Scholar
  81. 81.
    Yates AJ, Gutierrez GE, Smolens P, et al. Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption and bone metabolism. J Clin Invest 1988; 81:932–938.PubMedCrossRefGoogle Scholar
  82. 82.
    Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of prostate. Nat Med 1995; 1:944–949.PubMedCrossRefGoogle Scholar
  83. 83.
    Izbicka E, Dunstan C, Esparza J, Jacobs C, Sabatini M, Mundy GR. Human amniotic tumor which induces new bone formation in vivo produces a growth regulatory activity in vitro for osteoblasts identified as an extended from of basic fibroblast growth factor (bFGF). Cancer Res 1996; 56:633–636.PubMedGoogle Scholar
  84. 84.
    The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986; 315:1377–1381.Google Scholar
  85. 85.
    Lafitte JJ, Ribet ME, Prevost BM, Gosselin BH, Copin MC, Brichet AH. Postresection irradiation for T2N0M0 non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg 1996; 62:830–834.PubMedCrossRefGoogle Scholar
  86. 86.
    Stephens RJ, Girling DJ, Bleehen NM, Moghissi K, Yosef HM, Machin D. The role of post-operative radiotherapy in non-smallcell lung cancer: a multicenter randomized trial in patients with pathologically staged T1-2, N1-2, M0 disease. Br J Cancer 1996; 74:632–639.PubMedGoogle Scholar
  87. 87.
    PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: sytematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet 1998; 352:257–263.CrossRefGoogle Scholar
  88. 88.
    Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 2000; 343:1217–1222.PubMedCrossRefGoogle Scholar
  89. 89.
    Ohta M, Tsuchiya R, Shimoyama M, et al. Adjuvant chemotherapy for completely resected stage III non-small-cell lung cancer: results of a randomized prospective study. J Thorac Cardiovasc Surg 1993; 106:703–708.PubMedGoogle Scholar
  90. 90.
    Dautzenberg B, Chastang C, Arriagada R, et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma: a randomized trial of 267 patients. Cancer 1995; 76:779–786.PubMedCrossRefGoogle Scholar
  91. 91.
    The Study Group of Adjuvant Chemotherapy for Lung Cancer. A randomized trial of postoperative adjuvant chemotherapy in nonsmall cell lung cancer (the second cooperative study). Eur J Surg Oncol 1995; 21:69–77.CrossRefGoogle Scholar
  92. 92.
    Holmes EC, Gail M. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 1986; 4:710–715.PubMedGoogle Scholar
  93. 93.
    Xu G, Rong T, Lin P. Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: a randomized study on 70 patients. Chin Med J (Eng) 2000; 113:617–620.Google Scholar
  94. 94.
    Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311:899–909.Google Scholar
  95. 95.
    The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351–360.CrossRefGoogle Scholar
  96. 96.
    Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group. Cancer 1987; 59:1874–1881.PubMedCrossRefGoogle Scholar
  97. 97.
    Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323:940–945.PubMedGoogle Scholar
  98. 98.
    Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: sevenyear follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210–1215.PubMedCrossRefGoogle Scholar
  99. 99.
    Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer: a meta-analysis. Ann Intern Med 1996; 125:723–729. (Erratum, Ann Intern Med 1997; 126:670.)PubMedGoogle Scholar
  100. 100.
    Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stage IIIa and IIIb non small cell lung cancer: a meta-analysis. Cancer 1995; 76:593–601.PubMedCrossRefGoogle Scholar
  101. 101.
    Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692–2699.PubMedGoogle Scholar
  102. 102.
    Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003; 22:621.Google Scholar
  103. 103.
    Attar S, Krasna MJ, Sonett JR, et al. Superior sulcus (Pancoast) tumor: experience with 105 patients. Ann Thorac Surg 1998; 66:193–198.PubMedCrossRefGoogle Scholar
  104. 104.
    Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 2001; 121:472–483.PubMedCrossRefGoogle Scholar
  105. 105.
    Barnes JB, Johnson SB, Dahiya RS, Temes RT, Herman TS, Thomas CR Jr. Concomitant weekly cisplatin and thoracic radiotherapy for Pancoast tumors of the lung: pilot experience of the San Antonio Cancer Institute. Am J Clin Oncol 2002; 25:90–92.PubMedCrossRefGoogle Scholar
  106. 106.
    Gandhi S, Walsh GL, Komaki R, et al. A multidisciplinary surgical approach to superior sulcus tumors with vertebral invasion. Ann Thorac Surg 1999; 68:1778–1784.PubMedCrossRefGoogle Scholar
  107. 107.
    Skarin A, Jochelson M, Sheldon T, et al. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989; 40:266–274.PubMedCrossRefGoogle Scholar
  108. 108.
    Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86:673–680.PubMedCrossRefGoogle Scholar
  109. 109.
    Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing peroperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330:153–158.PubMedCrossRefGoogle Scholar
  110. 110.
    Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21:1–6.PubMedCrossRefGoogle Scholar
  111. 111.
    Rosell R, Gomez-Codina J, Camps C, et al. Preresctional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26:7–14.PubMedCrossRefGoogle Scholar
  112. 112.
    Dipierre A, Milleron B, Moro-Sibilot d, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20:247–253.CrossRefGoogle Scholar
  113. 113.
    Albain KS, Scott CB, Rusch VR, et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 2003; 22:621a.Google Scholar
  114. 114.
    Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only: a multicenter randomized phase III trial. Eur J Cancer 1998; 34:1036–1044.PubMedCrossRefGoogle Scholar
  115. 115.
    Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine, and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995; 71:366–370.PubMedGoogle Scholar
  116. 116.
    Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17:3188–3194.PubMedGoogle Scholar
  117. 117.
    Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122–130.PubMedGoogle Scholar
  118. 118.
    Gatzemeier U, von Pawel J, Gottfried M, et al. Phase III comparative study of high dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18:3390–3399.PubMedGoogle Scholar
  119. 119.
    Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 1998; 16:2459–2465.PubMedGoogle Scholar
  120. 120.
    Lilenbaum RC, Herndon J, List M, et al. Sing-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL) and cost-effectiveness. Prog Proc Am Soc Clin Oncol 2002; 21:1a.Google Scholar
  121. 121.
    Georgoulias V, Ardavanis A, Agelidou M, et al. Preliminary analysis of a multicenter phase III trial comparing docetaxel (D) versus docetaxel/cisplatin (DC) in patients with inoperable advanced and metastatic non-small cell lung cancer (NSCLC). Prog Proc Am Soc Clin Oncol 2002; 21:291a.Google Scholar
  122. 122.
    Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18:623–631.PubMedGoogle Scholar
  123. 123.
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92–98.PubMedCrossRefGoogle Scholar
  124. 124.
    Kelly K, Mikhaeel-Kamel N, Pan Z, Murphy J, Prindiville S, Bunn PA Jr. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res 2000; 6:3474–3479.PubMedGoogle Scholar
  125. 125.
    Frasci G, Panza N, Comella P, et al. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. J Clin Oncol 1999; 17:2316–2325.PubMedGoogle Scholar
  126. 126.
    The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91:66–72.CrossRefGoogle Scholar
  127. 127.
    Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362–372.PubMedGoogle Scholar
  128. 128.
    Ettinger DS. Is there a preferred combination chemotherapy regimen for metastatic non-small cell lung cancer? Oncologist 2002; 7:226–233.PubMedCrossRefGoogle Scholar
  129. 129.
    Smith IE, O’Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001; 19:1336-.PubMedGoogle Scholar
  130. 130.
    Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002; 20:1335–1343.PubMedCrossRefGoogle Scholar
  131. 131.
    Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095–2103.PubMedGoogle Scholar
  132. 132.
    Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18:2354–2362.PubMedGoogle Scholar
  133. 133.
    Magilligan DJ Jr, Duvernoy C, Malik G, Lewis JW Jr, Knighton R, Ausman JI. Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years’ experience. Ann Thorac Surg 1986; 42:360–364.PubMedCrossRefGoogle Scholar
  134. 134.
    Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494–500.PubMedGoogle Scholar
  135. 135.
    Raviv G, Klein E, Yellin A, Schneebaum S, Ben-Ari GSurgical treatment of solitary adrenal metastases from lung carcinoma. J Surg Oncol 1990; 43:123–124.PubMedCrossRefGoogle Scholar
  136. 136.
    Reyes L, Parvez Z, Nemoto T, Regal AM, Takita H. Adrenalectomy for adrenal metastasis from lung carcinoma. J Surg Oncol 1990; 44:32–34.PubMedCrossRefGoogle Scholar
  137. 137.
    Johnson DH. Gefitinib (Iressa) trials in non-small cell lung cancer. Lung Cancer 2003; 41:S23–S28.PubMedCrossRefGoogle Scholar
  138. 138.
    Kukunoor R, Shah J, Mekhail T. Targeted therapy for lung cancer. Current Oncol Rep 2003; 5:326–333.CrossRefGoogle Scholar
  139. 139.
    Aisner J, Alberto P, Bitran J, et al. Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep 1983; 67:37–43.PubMedGoogle Scholar
  140. 140.
    Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988; 15:278–299.PubMedGoogle Scholar
  141. 141.
    Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83:855–861.PubMedCrossRefGoogle Scholar
  142. 142.
    Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10:282–291.PubMedGoogle Scholar
  143. 143.
    Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618–1624.PubMedGoogle Scholar
  144. 144.
    Arriagada R, Pignon JP, Ihde DC, et al. Effect of thoracic radiotherapy on mortality in limited small cell lung cancer: a metaanalysis of 13 randomized trials among 2,140 patients. Anticancer Res 1994; 14:333–335.PubMedGoogle Scholar
  145. 145.
    Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20:3054–3060.PubMedCrossRefGoogle Scholar
  146. 146.
    Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265–271.PubMedCrossRefGoogle Scholar
  147. 147.
    Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D.. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study: Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol 1994; 21:23–30.PubMedGoogle Scholar
  148. 148.
    Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85–91.PubMedCrossRefGoogle Scholar
  149. 149.
    Niell HB, Herndon JE, Miller AA, et al. Randomized Phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC). Prog Proc Am Soc Clin Oncol 2002; 21:293a.Google Scholar
  150. 150.
    Mavroudis D, Papadakis E, Veslemes M, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatmetnt in patients with small-cell lung cancer. Ann Oncol 2001; 12:463–470.PubMedCrossRefGoogle Scholar
  151. 151.
    Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15:2090–2096.PubMedGoogle Scholar
  152. 152.
    Tchekmedyian S, Rosen LS, Gordon D, et al. Long-term efficacy and safety of zoledronic acid in reducing skeletal complications in patients with bone metastases from solid tumors. Proc Am Soc Clin Oncol 2003; 22:630a.Google Scholar
  153. 153.
    Lipton A. Bone metastases in breast cancer. Curr Treat Options Oncol 2003; 4:151–158.PubMedCrossRefGoogle Scholar
  154. 154.
    Eaton CL, Coleman RE. Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. Cancer Treat Rev 2003; 29:189–198.PubMedCrossRefGoogle Scholar
  155. 155.
    Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 2000; 18:1378–1391.PubMedGoogle Scholar
  156. 156.
    Yano S, Zhang H, Hanibuchi M, et al. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice. Clinc Cancer Res 2003; 9:5380–5285.Google Scholar
  157. 157.
    Hortobagyi GN. Novel approaches to the management of bone metastases. Semin Oncol 2003; 30:161–166.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, Inc., Totowa, NJ 2006

Authors and Affiliations

  • Jigar Shah
    • 1
  • Tarek Mekhail
    • 2
  1. 1.Department of Hematology and OncologyTaussig Cancer Center, The Cleveland Clinic FoundationCleveland
  2. 2.Lung Cancer ProgramThe Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic FoundationCleveland

Personalised recommendations